Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLEUSTAR-Enfometrial01: AZD8205 versus physician's choice chemotherapy in B7-H4-positive advanced or metastatic endometrial cancer
MOH_2025-11-19_015475Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of puxitatug samrotecan in endometrial cancer (EC) (2 arms), sponsored by AstraZeneca. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
puxitatug samrotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2025-11-19_015475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-19_015475.